CN110585103A - Breast enlarging plant composition, breast enlarging cream and preparation method - Google Patents
Breast enlarging plant composition, breast enlarging cream and preparation method Download PDFInfo
- Publication number
- CN110585103A CN110585103A CN201911047151.1A CN201911047151A CN110585103A CN 110585103 A CN110585103 A CN 110585103A CN 201911047151 A CN201911047151 A CN 201911047151A CN 110585103 A CN110585103 A CN 110585103A
- Authority
- CN
- China
- Prior art keywords
- breast
- cream
- mixing
- water
- enlarging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000481 breast Anatomy 0.000 title claims abstract description 194
- 239000006071 cream Substances 0.000 title claims abstract description 126
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 71
- 239000000284 extract Substances 0.000 claims abstract description 41
- 241000196324 Embryophyta Species 0.000 claims abstract description 35
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 30
- 239000003906 humectant Substances 0.000 claims abstract description 30
- 239000003974 emollient agent Substances 0.000 claims abstract description 28
- 230000003416 augmentation Effects 0.000 claims abstract description 26
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 14
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 14
- 239000001140 aloe barbadensis leaf extract Substances 0.000 claims abstract description 14
- 241000208680 Hamamelis mollis Species 0.000 claims abstract description 9
- 229940069638 aloe vera leaf extract Drugs 0.000 claims abstract description 9
- 229940118846 witch hazel Drugs 0.000 claims abstract description 9
- 229940106579 hops extract Drugs 0.000 claims abstract description 6
- 239000001906 humulus lupulus l. absolute Substances 0.000 claims abstract description 6
- 239000012071 phase Substances 0.000 claims description 84
- 238000002156 mixing Methods 0.000 claims description 60
- 239000003921 oil Substances 0.000 claims description 46
- 235000019198 oils Nutrition 0.000 claims description 46
- -1 polydimethylsiloxane Polymers 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 27
- 239000002562 thickening agent Substances 0.000 claims description 21
- 239000011259 mixed solution Substances 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000003755 preservative agent Substances 0.000 claims description 14
- 230000002335 preservative effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 230000002708 enhancing effect Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 230000001804 emulsifying effect Effects 0.000 claims description 9
- 238000005086 pumping Methods 0.000 claims description 9
- 239000000230 xanthan gum Substances 0.000 claims description 7
- 235000010493 xanthan gum Nutrition 0.000 claims description 7
- 229920001285 xanthan gum Polymers 0.000 claims description 7
- 229940082509 xanthan gum Drugs 0.000 claims description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 5
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 5
- 239000004386 Erythritol Substances 0.000 claims description 5
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 5
- 239000000828 canola oil Substances 0.000 claims description 5
- 235000019519 canola oil Nutrition 0.000 claims description 5
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- 235000019414 erythritol Nutrition 0.000 claims description 5
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 5
- 229940009714 erythritol Drugs 0.000 claims description 5
- 229930182478 glucoside Natural products 0.000 claims description 5
- 150000008131 glucosides Chemical class 0.000 claims description 5
- 229940075529 glyceryl stearate Drugs 0.000 claims description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 5
- 229940100460 peg-100 stearate Drugs 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- 230000003750 conditioning effect Effects 0.000 claims description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 3
- 229940119170 jojoba wax Drugs 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- 229940042585 tocopherol acetate Drugs 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- 240000007436 Cananga odorata Species 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 2
- 241000675108 Citrus tangerina Species 0.000 claims description 2
- 235000010254 Jasminum officinale Nutrition 0.000 claims description 2
- 240000005385 Jasminum sambac Species 0.000 claims description 2
- 241000220317 Rosa Species 0.000 claims description 2
- 240000000513 Santalum album Species 0.000 claims description 2
- 235000008632 Santalum album Nutrition 0.000 claims description 2
- 244000044822 Simmondsia californica Species 0.000 claims description 2
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims description 2
- 235000017803 cinnamon Nutrition 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 235000002020 sage Nutrition 0.000 claims description 2
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000001433 sodium tartrate Substances 0.000 claims description 2
- 229960002167 sodium tartrate Drugs 0.000 claims description 2
- 235000011004 sodium tartrates Nutrition 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 37
- 206010006242 Breast enlargement Diseases 0.000 abstract description 34
- 230000028327 secretion Effects 0.000 abstract description 14
- 238000011161 development Methods 0.000 abstract description 11
- 229940088597 hormone Drugs 0.000 abstract description 11
- 239000005556 hormone Substances 0.000 abstract description 11
- 230000001105 regulatory effect Effects 0.000 abstract description 9
- 230000003647 oxidation Effects 0.000 abstract description 7
- 238000007254 oxidation reaction Methods 0.000 abstract description 7
- 230000004936 stimulating effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 51
- 230000000052 comparative effect Effects 0.000 description 38
- 238000012360 testing method Methods 0.000 description 26
- 230000007794 irritation Effects 0.000 description 23
- 239000000523 sample Substances 0.000 description 15
- 210000005075 mammary gland Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 12
- 230000003020 moisturizing effect Effects 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 241000208681 Hamamelis virginiana Species 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 4
- 210000004216 mammary stem cell Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000009044 synergistic interaction Effects 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 206010006298 Breast pain Diseases 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 208000006662 Mastodynia Diseases 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940119485 safflower extract Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 206010006237 Breast dysplasia Diseases 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 244000089795 Clausena lansium Species 0.000 description 1
- 235000008738 Clausena lansium Nutrition 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 240000007890 Leonurus cardiaca Species 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010058680 Nipple swelling Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a breast enlarging plant composition, breast enlarging cream and a preparation method. The breast augmentation plant composition comprises aloe vera leaf extract, kudzu root extract, hops extract and witch hazel extract. The breast enlarging cream comprises the following components in percentage by weight: 0.5-10% of breast enlargement plant composition, 1-30% of humectant, 1-10% of emulsifier, 0.5-5% of skin conditioner, 1-30% of emollient and the balance of water. The breast enlargement plant composition has the advantages that the active components are matched with each other, the synergistic effect is realized, the effects of oxidation resistance, moisture preservation and water locking can be realized, the internal secretion of a human body can be effectively regulated, and the breast problem is fundamentally solved. The breast enlarging cream promotes the secondary development of breast tissues from outside to inside, and helps the secondary development of the breast tissues by stimulating the secretion of female hormones, thereby achieving the effect of fullness and firmness.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a breast enlarging plant composition, breast enlarging cream and a preparation method.
Background
With the development of the times, more and more women are still attacking unreplicated women silently due to the problems of irritability, depression and the like of emotion caused by the continuous increase of life and working pressure, and mammary gland diseases such as hyperplasia of mammary glands, mastitis and the like. The incidence of mammary gland of the unbelided female is basically equal to that of the married female. Moreover, most of the unmarried women have symptoms of breast distending pain or nipple swelling and itching pain before and after each menstruation, the breasts are sensitive at the time and grow rapidly, and the point of maintaining the breast shape well is the formation of a good breast shape. Meanwhile, with the increase of age or after pregnancy, skin is inactivated due to unsmooth qi and blood, aging is accelerated, the breast is prone to sagging, and the condition of loose skin causes endocrine dyscrasia, estrogen secretion reduction, insufficient breast nutrition supply, and further causes breast dysplasia and rough skin.
At present, cosmetics special for breast maintenance in the market lack scientific cognition on breast tissue dysplasia, senilism and relaxation, and the breast enlarging effect is not obvious and the alleged effect is not achieved. The use effect is repeated and irregular, and the breasts are restored after the use is stopped. Furthermore, some cosmetic formulations for breast care contain artificial hormones such as diethylstilbestrol and estradiol, which cause serious and persistent damages to women's bodies after long-term use.
CN105997640A discloses a breast enlarging skin care product containing plant components, which comprises the following components: grape polyphenol, Chinese wampee fruit flavone, hop flavone, motherwort flavone, kudzu root flavone, hydrolyzed collagen, grease, an emulsifier, a thickener, a humectant, a preservative, an aromatic and the balance of deionized water.
CN107468614A discloses a breast beautifying composition, which comprises a safflower extract, a hop extract, a yam extract, an angelica extract, a ginseng extract, a pueraria extract, soy isoflavone and a turmeric extract, wherein the breast beautifying composition is blindly added with breast enlarging plant components to achieve the breast enlarging effect, the skin is prone to local red swelling after use, and particularly the added safflower extract is prone to aggravate the excitation effect and allergic reaction of the nervous system, and severe allergic reaction can occur after long-term use.
Therefore, the development of a safe, effective and non-rebound breast-enlarging nursing product is the focus of current research in the field.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide the breast enlarging plant composition, the breast enlarging cream and the preparation method.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the present invention provides a breast enhancing botanical composition comprising aloe vera leaf extract, pueraria lobata extract, hops extract and hamamelis virginiana extract.
In the invention, the aloe vera leaf extract is mild in nature, contains various components for eliminating superoxide radicals, can make skin tender and elastic, and has the effects of preventing corrosion and delaying aging. In addition, the aloe vera leaf extract has the effects of astringing, softening, moisturizing, relieving sclerosing and keratinization of the skin, promoting cell regeneration, supporting the development of adipose tissues and ligaments around the breast with a shaping effect, and helping the maintenance of collagen fibers in the skin and the growth of new cells, and making the breast more plump and firmer.
In the invention, the wild pueraria lobata extract is rich in various isoflavone substances and has very good regulation effect on a human body, wherein active substances such as daidzin, daidzein, puerarin and the like have the functions of promoting blood flow, relaxing smooth muscles and relieving spasm, resisting cancer, inducing cancer cell differentiation, resisting oxidation and enhancing immunity. The wild pueraria extract has stronger activity on the skin of a human body, can not only ensure that a mammary gland develops for the second time and the breast is plump and firm, but also can permeate into breast tissues to promote the reconstruction of the breast tissues and ensure that the curve is more perfect.
In the invention, the hop extract rich in the hop can enter the mammary cells of the hop extract to promote the continuous secretion of hormones from the breast, so that the breast becomes more full and the dysplasia of the mammary gland is eliminated. In addition, the hop extract can regulate endocrine and resist climacteric syndrome, various alkaloids of the hop extract can regulate the functions of adrenal gland, pancreas, ovary and the like, balance the hormone level in the body, and rich taurine, protein and the like can regulate and repair physiological functions, improve qi and blood and relieve climacteric symptoms.
In the invention, the witch hazel extract has the effects of resisting free radicals, regulating sebum secretion, moisturizing and whitening, promoting lymphatic blood circulation, rapidly permeating into skin, comprehensively regulating skin from inside to outside, balancing the pH value and grease secretion of the skin, purifying pores, repairing damaged skin, effectively regulating diastolic pores, obviously converging coarse pores, and enabling the skin to rapidly present a fine, smooth and compact state.
In the invention, the breast enhancement plant composition comprises aloe barbadensis leaf extract, pueraria lobata extract, hops extract and hamamelis virginiana extract, and the active components are matched with each other, so that the breast enhancement plant composition has a synergistic effect, balances hormone secretion, regulates estrogen, is used for breast maintenance and can enable breasts to develop again; the breast skin care cream has the functions of regulating internal secretion, dredging channels and collaterals, activating mammary cells, repairing, dredging and tightening the breast skin, enhancing the activity of the breast skin, supplementing skin nutrition, having excellent oxidation resistance and moisturizing activity, lifting the skin around the breast, tightening and moistening the skin, and restoring the breast to stand and have a good appearance.
Preferably, the breast augmentation plant composition comprises the following components in parts by weight: 0.01-5 parts of aloe vera leaf extract, 0.5-5 parts of kudzu root extract, 0.5-5 parts of hop extract and 0.01-2 parts of witch hazel extract.
In the present invention, the content of the aloe vera leaf extract in the breast enhancing plant composition may be 0.01 to 5 parts, for example, 0.01 part, 0.02 part, 0.04 part, 0.06 part, 0.08 part, 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part, 1.5 part, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts.
In the present invention, the content of the pueraria lobata extract in the plant composition for enlarging breast may be 0.5 to 5 parts, for example, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part, 1.1 part, 1.2 part, 1.3 part, 1.4 part, 1.5 part, 1.6 part, 1.7 part, 1.8 part, 1.9 part, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts.
In the present invention, the hop extract is contained in the breast-enlarging plant composition in an amount of 0.5 to 5 parts, for example, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part, 1.1 part, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts.
In the present invention, the content of the hamamelis virginiana extract in the breast-enlarging plant composition may be 0.01 to 2 parts, for example, 0.01 part, 0.02 part, 0.04 part, 0.06 part, 0.08 part, 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part, 1.1 part, 1.2 part, 1.3 part, 1.4 part, 1.5 part, 1.6 part, 1.7 part, 1.8 part, 1.9 part, 2 parts.
In a second aspect, the invention provides a breast augmentation cream, which comprises the following components in percentage by weight: the breast enlargement plant composition according to the first aspect comprises 0.5-10% of a humectant, 1-30% of an emulsifier, 0.5-5% of a skin conditioner, 1-30% of an emollient, and the balance of water.
In the invention, the breast enlarging plant composition, the moisturizing agent, the emulsifying agent, the skin conditioning agent, the skin moistening agent and the water provided by the first aspect are reasonably matched to prepare the breast enlarging cream, the breast enlarging cream promotes the secondary development of breast tissues from outside to inside, and the secondary development of the breast tissues is assisted by stimulating the secretion of female hormones, so that the effect of plumpness and firmness is achieved. The use experience is comfortable, the skin absorption is easy, and the effects of re-developing breasts, lifting the skin around the breasts and recovering upright and plump breasts are achieved. The breast enlarging cream can penetrate through the surface layer of the skin to be absorbed, can induce endocrine, can effectively stimulate mammary cells and tissues, can enter deep organism to circulate, can accelerate the metabolism speed, can also effectively regulate and distribute the flow of fat at all parts of the whole body, can promote the fat to migrate around the breast, can fill and accumulate the breast enlarging cream, and can improve the breast function. Has good curative effect on solving the problems of small flat and loose breast, drooping, pain and swelling of the chest before and after menstruation, obstruction of mammary gland, hyperplasia of mammary glands and the like in the breast problem.
Preferably, the humectant is selected from any one or a combination of at least two of propylene glycol, butylene glycol, glycerol or erythritol.
As a preferred technical scheme, the humectant is a combination of propylene glycol, butanediol, glycerol and erythritol. The components are selected to be compounded to be used as the humectant. Mainly moisturizes, locks water, preserves moisture and nourishes, so that the problem of skin dryness is fundamentally solved for the skin, and the sensitive and uncomfortable symptoms caused by dryness are relieved.
Preferably, the emulsifier is selected from any one or a combination of at least two of cetearyl alcohol, cetearyl glucoside, glyceryl stearate or PEG-100 stearate.
As a preferred embodiment of the present invention, the emulsifier is a combination of cetearyl alcohol, cetearyl glucoside, glyceryl stearate and PEG-100 stearate.
Preferably, the skin conditioning agent is selected from tocopherol acetate and/or sodium hyaluronate.
Tocopheryl acetate, which belongs to vitamin E derivatives. The anti-aging health care product has the advantages that the anti-aging health care product can prevent cell membranes and unsaturated fatty acids and other easily-oxidized substances in cells from being oxidized in the process of metabolism of a human body, so that the integrity of the cell membranes is protected, the anti-aging effect is achieved, estrogen in the human body can be improved, the ovarian function is enhanced, follicles are increased, the gonad secretory cells of female friends are helped to increase the secretory function, and the breast enhancement effect is achieved.
Sodium hyaluronate has effects of resisting lipid peroxidation, reducing DNA fragmentation and protein oxidation, reducing generation of hydroxyl free radical, preventing lipid peroxidation, improving antioxidant defense ability, and reducing cell injury. The sodium hyaluronate can form a moisturizing breathable film on the skin of the chest, keep the skin moist and bright, and can permeate into the dermis to promote blood microcirculation, help to promote the penetration and absorption of nutrient components in breast cream, further promote the skin around the chest to be compact, moist and elastic, and recover the chest to be upright and elastic.
Preferably, the emollient is selected from any one or a combination of at least two of jojoba oil, canola oil, polydimethylsiloxane, caprylic/capric triglyceride, or isopropyl myristate.
As a preferred embodiment of the present invention, the emollient is a combination of jojoba oil, canola oil, polydimethylsiloxane, caprylic/capric triglyceride, and isopropyl myristate.
Preferably, the breast augmentation cream further comprises a thickener.
Preferably, the weight percentage of said thickener in said breast augmentation cream is 0.1-1%, for example 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%.
Preferably, the thickening agent is selected from any one or a combination of at least two of xanthan gum, arabic gum, ammonium acryloyldimethyl taurate/VP copolymer or polyacrylate crosslinked polymer-6, preferably xanthan gum.
The xanthan gum can increase the stability of the breast enlargement cream system, and can adjust the rheological property of the breast enlargement cream by utilizing the good thixotropy or pseudoplasticity of the xanthan gum, thereby improving the touch feeling of the breast enlargement cream after use. In addition, xanthan gum also has a moisturizing effect, and it has a hydrophilic group, and combines with hydrogen in water to achieve the moisturizing effect.
Preferably, the breast augmentation cream further comprises a preservative.
Preferably, the weight percentage of the preservative in the breast augmentation cream is 0.5-1%, for example, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%.
Preferably, the preservative is selected from any one or a combination of at least two of methylparaben, phenoxyethanol or ethylhexyl glycerin.
Preferably, the breast augmentation cream further comprises a pH regulator.
Preferably, the weight percentage of the pH regulator in the breast augmentation cream is 0.1-1%.
Preferably, the pH regulator is selected from any one or a combination of at least two of sodium citrate, sodium tartrate, diethanolamine or triethanolamine, preferably triethanolamine.
Preferably, the breast augmentation cream further comprises essence.
Preferably, the weight percentage of the essence in the breast-enlarging cream is 0.01-0.3%, for example, 0.01%, 0.02%, 0.04%, 0.06%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%.
Preferably, the essence is selected from any one of or a combination of at least two of rose essence, jasmine essence, cinnamon essence, tangerine essence, ylang-ylang essence, sandalwood essence and sage essence.
Preferably, the breast enlargement cream comprises the following components in percentage by weight: 0.5-10% of the plant breast enlargement composition according to the first aspect, 1-10% of propylene glycol, 0.1-1% of butylene glycol, 3-10% of glycerol, 0.1-1% of erythritol, 0.1-3% of cetearyl alcohol, 0.1-3% of cetearyl glucoside, 0.1-2% of glyceryl stearate, 0.1-2% of PEG-100 stearate, 0.1-1% of tocopherol acetate, 0.5-3% of sodium hyaluronate, 0.5-3% of jojoba seed oil, 1-5% of canola oil, 1-5% of polydimethylsiloxane, 1-10% of caprylic/capric triglyceride, 1-10% of isopropyl myristate, 0.1-1% of thickening agent, 0.5-1% of preservative, 0.1-1% of pH regulator and 0.01-0.3% of essence, and the balance of water.
In a third aspect, the present invention provides a method for preparing the breast augmentation cream according to the second aspect, wherein the method comprises the following steps:
(1) mixing the humectant, emulsifier, skin conditioner, emollient and the water phase components with water to obtain water phase mixed solution; mixing oil phase components in the humectant, the emollient and the emulsifier to obtain oil phase mixed liquor;
(2) mixing the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) and homogenizing to obtain homogenized liquor;
(3) mixing the homogenized liquid obtained in the step (2) with the breast enhancement plant composition to obtain the breast enhancement cream.
Preferably, the temperature at which the aqueous phase component and water are mixed in step (1) is 80 to 85 ℃, and may be, for example, 80 ℃, 81 ℃, 82 ℃, 83 ℃, 84 ℃, or 85 ℃.
Preferably, the time for mixing the water phase component and water in step (1) is 5-10min, such as 5min, 5.5min, 6min, 6.5min, 7min, 7.5min, 8min, 8.5min, 9min, 9.5min or 10 min.
Preferably, the temperature at which the oil phase components are mixed in step (1) is 78 to 80 ℃, and may be, for example, 78 ℃, 78.5 ℃, 79 ℃, 79.5 ℃ or 80 ℃.
Preferably, the time for mixing the oil phase components in step (1) is 5-10min, such as 5min, 5.5min, 6min, 6.5min, 7min, 7.5min, 8min, 8.5min, 9min, 9.5min or 10 min.
Preferably, the temperature for mixing and homogenizing in the step (2) is 80-82 ℃, for example, 80 ℃, 80.5 ℃, 81 ℃, 81.5 ℃ or 82 ℃ and the like.
Preferably, the mixing and homogenizing time in the step (2) is 10-15min, such as 10min, 11min, 12min, 13min, 14min or 15 min.
Preferably, the temperature of the mixing in step (3) is 40-45 ℃, for example, 40 ℃, 41 ℃, 42 ℃, 43 ℃, 44 ℃ or 45 ℃ and the like.
Preferably, the mixing time in step (3) is 10-20min, for example, 10min, 11min, 12min, 13min, 14min, 15min, 16min, 17min, 18min, 19min or 20min, etc.
Preferably, the preparation method comprises the following steps:
(1) adding humectant, emulsifier, skin conditioner, emollient and water phase components and water into water phase pot, stirring and mixing at 80-85 deg.C for 5-10min to obtain water phase mixed solution; adding oil phase components of humectant, emulsifier, skin conditioner, and emollient into oil phase pot, stirring and mixing at 78-80 deg.C for 5-10min to obtain oil phase mixed solution;
(2) pumping the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) into an emulsifying pot, and mixing and homogenizing at 80-82 ℃ for 10-15min to obtain a homogeneous liquid;
(3) and (3) stirring and mixing the homogenized solution obtained in the step (2) and the breast enhancement plant composition of the first aspect at 40-45 ℃ for 10-20min to obtain the breast enhancement cream.
Preferably, the preparation method comprises the following steps:
(1) adding humectant, emulsifier, skin conditioner, emollient, thickener and water into water phase pot, stirring and mixing at 80-85 deg.C for 5-10min to obtain water phase mixed solution; adding oil phase components of humectant, emulsifier, skin conditioner, emollient, and thickener into oil phase pot, stirring and mixing at 78-80 deg.C for 5-10min to obtain oil phase mixed solution;
(2) pumping the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) into an emulsifying pot, and mixing and homogenizing at 80-82 ℃ for 10-15min to obtain a homogeneous liquid;
(3) and (3) stirring and mixing the homogenized solution obtained in the step (2) with the breast enhancement plant composition, the preservative, the pH regulator and the essence at 40-45 ℃ for 10-20min to obtain the breast enhancement cream.
Compared with the prior art, the invention has the following beneficial effects:
(1) the breast enhancement plant composition comprises an aloe barbadensis leaf extract, a kudzu vine root extract, a hop extract and a witch hazel extract, and active components are matched with each other to realize synergistic interaction, so that the breast enhancement plant composition is beneficial to balancing hormone secretion and regulating estrogen, plays a role in regulating internal endocrine, activates mammary cells, is mild, skin-friendly and easy to absorb, repairs and dredges breast skin, enhances breast skin activity, supplements skin nutrition, has excellent oxidation resistance, and promotes the skin around the breast to recover the breast to be compact and smooth.
(2) The breast enlarging cream provided by the invention can promote the secondary development of breast tissues from outside to inside, and can help the secondary development of the breast tissues by stimulating the secretion of female hormones, so that the effect of fullness and firmness is achieved. The breast enlarging cream can enter a deep organism to circulate through the surface layer of the skin, so that the metabolism speed is accelerated, the flow of fat at all parts of the whole body is effectively regulated and distributed, the fat is promoted to migrate to the periphery of the breast, the breast enlarging filling and accumulation are carried out, and the breast enlarging cream has an excellent skin care effect of enlarging and strengthening the breast.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Example 1
The embodiment provides breast enlargement cream which comprises the following components in percentage by weight:
the breast enlarging cream of the embodiment is prepared as follows:
(1) adding humectant, emulsifier, skin conditioner, emollient and water phase components and water into water phase pot, stirring and mixing at 80 deg.C for 10min to obtain water phase mixed solution; adding oil phase components in humectant, emulsifier, skin conditioner and emollient into oil phase pot, stirring and mixing at 78 deg.C for 10min to obtain oil phase mixed solution;
(2) pumping the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) into an emulsifying pot, and mixing and homogenizing at 82 ℃ for 15min to obtain a homogeneous liquid;
(3) and (3) stirring and mixing the homogenized solution obtained in the step (2) and the breast enlarging plant composition at 40 ℃ for 20min to obtain the breast enlarging cream.
Example 2
The embodiment provides breast enlargement cream which comprises the following components in percentage by weight:
the breast enlarging cream of the embodiment is prepared as follows:
(1) adding humectant, emulsifier, skin conditioner, emollient, thickener and water into water phase pot, stirring and mixing at 85 deg.C for 5min to obtain water phase mixed solution; adding oil phase components of humectant, emulsifier, skin conditioner, emollient, and thickener into oil phase pot, stirring and mixing at 80 deg.C for 5min to obtain oil phase mixed solution;
(2) pumping the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) into an emulsifying pot, and mixing and homogenizing at 80 ℃ for 10min to obtain a homogeneous liquid;
(3) and (3) stirring and mixing the homogenized solution obtained in the step (2) with the breast enhancement plant composition, the preservative, the pH regulator and the essence at 45 ℃ for 10min to obtain the breast enhancement cream.
Example 3
The embodiment provides breast enlargement cream which comprises the following components in percentage by weight:
the breast enlarging cream of the embodiment is prepared as follows:
(1) adding humectant, emulsifier, skin conditioner, emollient, thickener and water into water phase pot, stirring and mixing at 85 deg.C for 5min to obtain water phase mixed solution; adding oil phase components of humectant, emulsifier, skin conditioner, emollient, and thickener into oil phase pot, stirring and mixing at 80 deg.C for 5min to obtain oil phase mixed solution;
(2) pumping the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) into an emulsifying pot, and mixing and homogenizing at 80 ℃ for 10min to obtain a homogeneous liquid;
(3) and (3) stirring and mixing the homogenized solution obtained in the step (2) with the breast enhancement plant composition, the preservative, the pH regulator and the essence at 45 ℃ for 10min to obtain the breast enhancement cream.
Example 4
The embodiment provides breast enlargement cream which comprises the following components in percentage by weight:
the breast enlarging cream of the embodiment is prepared as follows:
(1) adding humectant, emulsifier, skin conditioner, emollient, thickener and water into water phase pot, stirring and mixing at 85 deg.C for 5min to obtain water phase mixed solution; adding oil phase components of humectant, emulsifier, skin conditioner, emollient, and thickener into oil phase pot, stirring and mixing at 80 deg.C for 5min to obtain oil phase mixed solution;
(2) pumping the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) into an emulsifying pot, and mixing and homogenizing at 80 ℃ for 10min to obtain a homogeneous liquid;
(3) and (3) stirring and mixing the homogenized solution obtained in the step (2) with the breast enhancement plant composition, the preservative, the pH regulator and the essence at 45 ℃ for 10min to obtain the breast enhancement cream.
Example 5
The embodiment provides breast enlargement cream which comprises the following components in percentage by weight:
the breast enlarging cream of the embodiment is prepared as follows:
(1) adding humectant, emulsifier, skin conditioner, emollient, thickener and water into water phase pot, stirring and mixing at 85 deg.C for 5min to obtain water phase mixed solution; adding oil phase components of humectant, emulsifier, skin conditioner, emollient, and thickener into oil phase pot, stirring and mixing at 80 deg.C for 5min to obtain oil phase mixed solution;
(2) pumping the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) into an emulsifying pot, and mixing and homogenizing at 80 ℃ for 10min to obtain a homogeneous liquid;
(3) and (3) stirring and mixing the homogenized solution obtained in the step (2) with the breast enhancement plant composition, the preservative, the pH regulator and the essence at 45 ℃ for 10min to obtain the breast enhancement cream.
Example 6
The embodiment provides breast enlargement cream which comprises the following components in percentage by weight:
the breast cream of this example was prepared in the same manner as in example 5.
Example 7
The embodiment provides breast enlargement cream which comprises the following components in percentage by weight:
the breast cream of this example was prepared in the same manner as in example 5.
Example 8
The embodiment provides breast enlargement cream which comprises the following components in percentage by weight:
the breast cream of this example was prepared in the same manner as in example 5.
Example 9
The embodiment provides breast enlargement cream which comprises the following components in percentage by weight:
the breast cream of this example was prepared in the same manner as in example 5.
Example 10
The embodiment provides breast enlargement cream which comprises the following components in percentage by weight:
the breast cream of this example was prepared in the same manner as in example 5.
Comparative example 1
This comparative example provides a breast cream which differs from example 5 only in that it does not contain the breast enhancing botanical composition and the other components and preparation method are the same as example 5.
Comparative example 2
This comparative example provides a breast cream, which is different from example 5 in that the breast cream does not contain aloe vera leaf extract, the pueraria lobata extract is 1.4% by weight, the hops extract is 1.4% by weight, and the witch hazel extract is 0.5% by weight, and other components and preparation methods are the same as example 5.
Comparative example 3
The comparative example provides a breast cream, which is different from example 5 in that the breast cream does not contain pueraria lobata extract, the weight percentage of aloe barbadensis leaf extract is 1%, the weight percentage of hops extract is 1.6%, the weight percentage of witch hazel extract is 0.7%, and other components and preparation methods are the same as example 5.
Comparative example 4
This comparative example provides a breast cream, which is different from example 5 in that the breast cream does not contain a hop extract, the aloe barbadensis leaf extract is 1 wt%, the pueraria lobata extract is 1.6 wt%, the witch hazel extract is 0.7 wt%, and other components and preparation methods are the same as example 5.
Comparative example 5
This comparative example provides a breast cream, which is different from example 5 in that the breast cream does not contain hamamelis virginiana extract, the aloe barbadensis leaf extract is 0.7 wt%, the pueraria lobata extract is 1.3 wt%, the hop extract is 1.3 wt%, and other components and preparation methods are the same as example 5.
Test example 1
Safety irritation test
(1) Haemolysis test of erythrocytes
Preparation of erythrocyte suspension: selecting healthy rabbits, taking 9mL of blood from heart, adding 1mL of 2% potassium oxalate solution, centrifuging, discarding supernatant, diluting the precipitate to 20mL with 20mmol/L PBS solution, and storing at 4 ℃ for later use. Breast augmentation cream and breast augmentation cream pair prepared in examples 1-10 were selectedThe breast augmentation cream prepared in the proportion of 1-5 is diluted to different concentrations by PBS solution, and each sample is provided with 5 concentration gradients. Adding 200 μ L of the above erythrocyte suspension (final concentration of the sample is controlled to be 5, 10, 20, 50, 100mg/mL respectively) into 10mL of diluent of the sample to be tested, taking distilled water as total blood-dissolving control, taking PBS solution as negative control, mixing gently, incubating at 37 deg.C for 30min, centrifuging at 2000r/min for 10min, collecting supernatant, and testing its absorbance at 560nm with spectrophotometer (A)560) Calculating the hemolysis rate according to the following formula;
a standard curve of hemolysis rate vs. sample concentration was plotted, and the sample concentration at which hemolysis occurred in 50% erythrocytes (HD) was calculated50)。
(2) Protein denaturation experiments:
diluting the breast enhancement cream prepared in examples 1-10 and the breast enhancement cream prepared in comparative examples 1-5 to 10g/L with PBS solution, taking 10mL of the dilution of the sample to be tested, adding 200 μ L of the erythrocyte suspension, using distilled water as a blank control, using 1mg/mL of Sodium Dodecyl Sulfate (SDS) solution as a positive control, mixing the two solutions gently, incubating the mixture at 37 ℃ for 30min, centrifuging the mixture at 2000r/min for 10min, taking the supernatant, and testing the absorbances A of the supernatant at 540nm and 575nm respectively by using a spectrophotometer540And A575Calculating a protein Denaturation Index (DI) according to the following formula;
wherein R is1Blank control group a575Blank control group A540，R2Experimental group a575Experimental group A540，R3Positive control group A575Positive control group A540。
Evaluating the irritation of the sample to be tested according to the L/D value, wherein the L/D value is HD50DI, erythrocyte hemolysis assay irritation grading criteria are shown in Table 1 below:
TABLE 1
| L/D | Grading |
| ﹥100 | Has no irritation |
| 10﹤L/D≤100 | Micro-stimulation property |
| 1﹤L/D≤10 | Mild irritation |
| 0.1﹤L/D≤1 | Moderate irritation |
| L/D≤0.1 | Severe irritation |
The results of the above-described hemolysis test and protein denaturation test are shown in Table 2 below:
TABLE 2
| Test sample | HD50(mg/L) | DI(％) | L/D | Evaluation of |
| Example 1 | 24729 | 1.00 | ﹥100 | Has no irritation |
| Example 2 | 20465 | 1.07 | ﹥100 | Has no irritation |
| Example 3 | 21124 | 1.06 | ﹥100 | Has no irritation |
| Example 4 | 21567 | 1.07 | ﹥100 | Has no irritation |
| Example 5 | 20725 | 1.05 | ﹥100 | Has no irritation |
| Example 6 | 19893 | 1.10 | ﹥100 | Has no irritation |
| Example 7 | 19863 | 1.12 | ﹥100 | Has no irritation |
| Example 8 | 19741 | 1.11 | ﹥100 | Has no irritation |
| Example 9 | 19831 | 1.12 | ﹥100 | Has no irritation |
| Example 10 | 19620 | 1.15 | ﹥100 | Has no irritation |
| Comparative example 1 | 9735 | 1.89 | ﹥100 | Has no irritation |
| Comparative example 2 | 12567 | 1.45 | ﹥100 | Has no irritation |
| Comparative example 3 | 12149 | 1.70 | ﹥100 | Has no irritation |
| Comparative example 4 | 12568 | 1.78 | ﹥100 | Has no irritation |
| Comparative example 5 | 14671 | 1.49 | ﹥100 | Has no irritation |
According to the test results, the stimulation of the breast enlargement cream prepared in the embodiments 1 to 10 of the invention is classified as non-stimulation, which shows that the breast enlargement cream has the characteristics of mildness and no stimulation; the sample concentration HD of the breast-enlarging cream prepared by the invention when 50% red blood cells are hemolyzed50Over 19000mg/L, is far greater than HD of breast enlargement cream prepared in comparative examples 1-550Meanwhile, the protein denaturation index DI is below 1.2 percent and is obviously smaller than that of the breast enlargement cream prepared in the comparative examples 1-5, which shows that the components of the breast enlargement cream are mutually matched, so that the toxic and side effects and irritation of the breast enlargement cream can be obviously reduced after synergistic interaction, and the breast enlargement cream is safer and more reliable.
Test example 2
Test for Oxidation resistance
The breast cream prepared in examples 1 to 10 and the breast cream prepared in comparative examples 1 to 5 were dissolved in an aqueous ethanol solution to prepare a sample solution having a concentration of 1%, and the following tests were performed:
(1) evaluation test of superoxide anion radical scavenging ability
4.5mL of 0.05mol/L Tris-HCl buffer solution with pH 8.2 was preheated in a 25 ℃ water bath for 30 min. Then adding 1mL of sample solution and 0.4mL of 25mol/L pyrogallol solution, mixing uniformly, reacting in a water bath at 25 ℃ for 5min, and adding 1mL of 8mol/L HCl to stop the reaction. Absorbance values were measured at 299nm with Tris-HCl buffer as reference. The blank control group replaced the sample solution with 1mL of the solvent of the sample solution. Superoxide anion radical scavenging rate (%) ([ 1- (A)y/Ak)]X 100%, wherein AkAbsorbance value for blank control, AyThe absorbance values for the sample sets.
(2) Evaluation test of hydroxyl radical scavenging ability
2mmol/L FeSO are added into a 25mL cuvette in turn4 3mL，1mmol/L H2O23mL, shaking up, then adding 3mL of salicylic acid with the concentration of 6mmol/L, shaking up, heating in a water bath at 37 ℃ for 15min, taking out, and measuring the absorbance; adding sample solutions with certain concentrations, shaking, heating in water bath for 15min, taking out, and measuring absorbance. Hydroxyl radical clearance (%) ═ a0-Ax-(A0-Ax0)]/A0X 100%, wherein A0、Ax、Ax0The absorbance values of the reaction system before adding no sample, the system after removing hydroxyl radicals from the sample and the system after removing hydroxyl radicals from the sample solvent are respectively shown.
The results of the breast-enhancement creams prepared in examples 1 to 10 and the breast-enhancement creams prepared in comparative examples 1 to 5, which were tested for their ability to scavenge superoxide anion radicals and hydroxyl radicals, are shown in Table 3.
TABLE 3
| Experimental project | Superoxide anion radical scavenging ratio (%) | Hydroxyl radical scavenging rate (%) |
| Example 1 | 90.50 | 90.41 |
| Example 2 | 94.12 | 94.65 |
| Example 3 | 94.65 | 95.67 |
| Example 4 | 96.71 | 97.35 |
| Example 5 | 96.85 | 97.26 |
| Example 6 | 92.12 | 91.89 |
| Example 7 | 90.62 | 90.99 |
| Example 8 | 90.98 | 90.94 |
| Example 9 | 91.12 | 91.22 |
| Example 10 | 93.12 | 92.22 |
| Comparative example 1 | 38.87 | 39.99 |
| Comparative example 2 | 56.34 | 55.46 |
| Comparative example 3 | 45.34 | 46.01 |
| Comparative example 4 | 42.76 | 45.42 |
| Comparative example 5 | 52.96 | 53.02 |
The above experiments show that the breast enhancement cream prepared in the application examples 1-10 of the present invention has a superoxide anion removal rate of more than 90% and a hydroxyl radical removal rate of more than 90%, which indicates that the breast enhancement cream of the present invention has significant effects of radical removal and oxidation resistance. The breast enlarging cream prepared in the comparative examples 1-5 has no ideal removal rate of superoxide anion free radicals and hydroxyl free radicals, and the breast enlarging cream has the advantages that the active components are matched with each other, the synergistic effect is realized, the oxidation resistance is improved, the tightness and elasticity of breast muscles are further improved, and the purposes of enlarging breasts and beautifying breasts are achieved.
Test example 3
In vitro weighing method moisturizing performance test research
The breast augmentation cream prepared in examples 1 to 10 and the breast augmentation cream prepared in comparative examples 1 to 5 were weighed to be 0.2g, respectively, and uniformly coated on a 5cm by 5cm glass plate to which a microporous air permeable tape was attached, and the glass plate was placed in a constant temperature and humidity dryer, and the mass of the glass plate after being placed for 2 hours and 4 hours was measured, respectively, and the moisture retention rate was calculated. The moisture retention rate calculation formula is as follows: moisture retention rate inhibition rate/% (M)2-M0)/(M1-M0)×100％。
Wherein M is0Is the mass/g, M, of the glass sheet1For the mass/g, M of the glass plate after sample application2The glass sheet mass/g after standing in the desiccator for several hours.
The experimental results of the in vitro weighing method for measuring the moisture retention rate of the breast cream prepared in the embodiments 1 to 10, the breast cream prepared in the comparative examples 1 to 5 and the glycerin serving as the control sample are shown in the following table 4:
TABLE 4
| Sample (I) | 2h moisture retention (%) | 4h moisture retention (%) |
| Example 1 | 86.6 | 75.9 |
| Practice ofExample 2 | 91.5 | 81.5 |
| Example 3 | 92.9 | 82.1 |
| Example 4 | 93.3 | 83.8 |
| Example 5 | 94.5 | 84.3 |
| Example 6 | 89.9 | 79.6 |
| Example 7 | 89.3 | 79.8 |
| Example 8 | 89.9 | 79.6 |
| Example 9 | 90.0 | 79.9 |
| Example 9 | 91.0 | 80.6 |
| Comparative example 1 | 66.6 | 39.2 |
| Comparative example 2 | 72.6 | 49.4 |
| Comparative example 3 | 70.5 | 44.1 |
| Comparative example 4 | 72.6 | 45.3 |
| Comparative example 5 | 70.6 | 47.6 |
The experiments show that the moisture retention rate of the breast enlargement cream prepared in the application examples 1-10 is still as high as 75% or more after 4 hours, and the breast enlargement cream has good moisture retention effect. The breast enlargement cream prepared in the comparative examples 1-5 has unsatisfactory moisturizing rate and moisturizing stability, and shows that the breast enlargement cream disclosed by the invention has a synergistic interaction effect due to the mutual cooperation of the active components, has an excellent moisturizing effect, can fundamentally relieve the problems of dryness and water loss of breast skin, further improves the firmness and elasticity of breast muscles, and achieves the purposes of enlarging and beautifying breast.
Test example 4
Estrogen effect test in mice
The test method comprises the following steps: 80 24-day-old female SD rats were randomly divided into 16 groups of 5 rats each after 1 week of pre-test in natural light. Daily at 8:00 am and 20:00 pm by 0.01g/10cm2The dosage is 10g/L breast enlargement cream prepared in examples 1-10 and breast enlargement cream prepared in comparative examples 1-5 are respectively smeared on each group of mice twice, deionized water is smeared on a blank control group twice a day,the smearing part is the abdomen of the mouse after the hair is scraped. Two weeks later, the rats were sacrificed and jugular blood was collected and centrifuged at 3000rpm at 4 ℃ for 30min to prepare serum, which was stored at-20 ℃ for testing. The method for measuring the content of the serum hormones is to carry out the radioimmunoassay measurement on estradiol and progesterone according to the specification of a radioimmunoassay kit, and the specific test results are shown in table 5.
TABLE 5
The test results show that the contents of estradiol and progesterone in the serum of the rat coated with the breast enhancement cream prepared in the examples 1-10 are obviously increased, the content of estradiol is more than 155pg/mL, and the content of progesterone is more than 0.90pg/mL, while the improvement level of each hormone in the serum of the rat coated with the breast enhancement cream prepared in the comparative examples 1-5 is far lower than that of the breast enhancement cream prepared in the application, which shows that the breast enhancement cream has reasonable compatibility of each active component, can promote the secretion of estrogen in a balanced manner by synergistic interaction, has the function of promoting the synchronous coordinated rise of the levels of female and progestogen, avoids the pathological influence of imbalance of the proportion of female and progestogen on the organ tissue structure, helps to solve the problem of breast tissue and achieves the effect of fullness and firmness.
Test example 5
Human breast enlargement curative effect test
Female volunteers 450 with healthy breasts were selected, all between the ages of 20-40, with different breast problems, but within two months of no treatment, and were divided into 15 groups of 30 people, 30 people in each group: 10 people with smaller breasts, 10 people with loose ptosis and 10 people with hyperplasia of mammary glands. The 15 women then applied the breast augmentation creams prepared in examples 1-10 and the breast augmentation creams prepared in comparative examples 1-5, respectively, 2 times a day and applied the same breast massage technique until the creams were completely absorbed for 90 days. The breast size was measured before and after use.
Breast enlargement curative effect evaluation standard: the effect is that the bust is increased or the breast is lifted by more than 5cm, the effect is obvious when the bust is more than 3cm, the effect is effective when the bust is more than 1cm, and the effect is ineffective when the bust is less than 1 cm. Evaluation standard of curative effect of hyperplasia of mammary glands: the lump disappears, the breast pain disappears, and the lump does not relapse after stopping taking the medicine for 3 months; the lump is reduced by over 1/2, and the breast pain disappears with obvious effect; the lump is reduced 1/3, the breast pain is relieved; the mass was unchanged or enlarged, and pain was not relieved, with specific test results as shown in table 6:
TABLE 6
The above test results show that the breast cream prepared in the embodiments 1 to 10 of the present invention has a good curative effect on solving the problems of small flat breast, loose and drooping breast, pain and swelling of breast before and after menstruation, obstruction of mammary gland, hyperplasia of mammary glands, etc. in the breast problems, and the test results of the breast cream prepared in the comparative examples 1 to 5 show that the breast cream has a far inferior efficacy on solving the problems of breast, and is difficult to solve the problems of obstruction of mammary gland and hyperplasia of mammary glands, which further indicates that the breast cream has reasonable compatibility of active components, has a synergistic effect, can promote the secondary development of breast tissue from outside to inside, helps the secondary development of breast tissue by stimulating the secretion of female hormone, has the functions of regulating internal secretion, dredging channels and collaterals, activating mammary gland cells, and enabling the breast fat cells to develop again, achieving the purpose of enlarging breast and beautifying breast.
The applicant states that the present invention is illustrated by the above examples to provide the plant composition, cream and preparation method for breast enlargement, but the present invention is not limited to the above examples, i.e. it is not meant to be dependent on the above examples to practice the present invention. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
Claims (10)
1. A breast enhancing botanical composition comprising aloe vera leaf extract, kudzu root extract, hops extract and witch hazel extract.
2. The breast enhancing plant composition of claim 1, wherein said breast enhancing plant composition comprises, in parts by weight: 0.01-5 parts of aloe vera leaf extract, 0.5-5 parts of kudzu root extract, 0.5-5 parts of hop extract and 0.01-2 parts of witch hazel extract.
3. The breast enlarging cream is characterized by comprising the following components in percentage by weight: the breast enhancement botanical composition of claim 1 or 2 comprising 0.5-10%, humectant 1-30%, emulsifier 1-10%, skin conditioner 0.5-5%, emollient 1-30%, and balance water.
4. The breast augmentation cream of claim 3, wherein said humectant is selected from any one or a combination of at least two of propylene glycol, butylene glycol, glycerin or erythritol;
preferably, the emulsifier is selected from any one or a combination of at least two of cetearyl alcohol, cetearyl glucoside, glyceryl stearate or PEG-100 stearate;
preferably, the skin conditioning agent is selected from tocopherol acetate and/or sodium hyaluronate;
preferably, the emollient is selected from any one or a combination of at least two of jojoba oil, canola oil, polydimethylsiloxane, caprylic/capric triglyceride, or isopropyl myristate.
5. The breast augmentation cream of claim 3 or 4, further comprising a thickening agent;
preferably, the weight percentage of the thickening agent in the breast augmentation cream is 0.1-1%;
preferably, the thickening agent is selected from any one or a combination of at least two of xanthan gum, arabic gum, ammonium acryloyldimethyl taurate/VP copolymer or polyacrylate crosslinked polymer-6, preferably xanthan gum;
preferably, the breast augmentation cream further comprises a preservative;
preferably, the weight percentage of the preservative in the breast augmentation cream is 0.5-1%;
preferably, the preservative is selected from any one or a combination of at least two of methyl hydroxybenzoate, phenoxyethanol or ethylhexyl glycerol;
preferably, the breast augmentation cream further comprises a pH regulator;
preferably, the weight percentage of the pH regulator in the breast enhancement cream is 0.1-1%;
preferably, the pH regulator is selected from any one or combination of at least two of sodium citrate, sodium tartrate, diethanolamine or triethanolamine, preferably triethanolamine;
preferably, the breast enlarging cream further comprises essence;
preferably, the weight percentage of the essence in the breast augmentation cream is 0.01-0.3%;
preferably, the essence is selected from any one of or a combination of at least two of rose essence, jasmine essence, cinnamon essence, tangerine essence, ylang-ylang essence, sandalwood essence and sage essence.
6. The breast enhancing cream of any one of claims 3 to 5, wherein the cream comprises in weight percent: the breast enhancing botanical composition of claim 1 or 2 0.5-10%, propylene glycol 1-10%, butylene glycol 0.1-1%, glycerin 3-10%, erythritol 0.1-1%, cetearyl alcohol 0.1-3%, cetearyl glucoside 0.1-3%, glyceryl stearate 0.1-2%, PEG-100 stearate 0.1-2%, tocopheryl acetate 0.1-1%, 0.5-3% of sodium hyaluronate, 0.5-3% of jojoba seed oil, 1-5% of canola oil, 1-5% of polydimethylsiloxane, 1-10% of caprylic/capric triglyceride, 1-10% of isopropyl myristate, 0.1-1% of thickening agent, 0.5-1% of preservative, 0.1-1% of pH regulator and 0.01-0.3% of essence, and the balance of water.
7. A method of preparing a breast augmentation cream as claimed in any one of claims 3 to 6, wherein the method comprises the steps of:
(1) mixing the humectant, emulsifier, skin conditioner, emollient and the water phase components with water to obtain water phase mixed solution; mixing oil phase components in the humectant, the emollient and the emulsifier to obtain oil phase mixed liquor;
(2) mixing the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) and homogenizing to obtain homogenized liquor;
(3) mixing the homogenized solution obtained in step (2) with the breast-enlarging plant composition of claim 1 or 2 to obtain the breast-enlarging cream.
8. The method according to claim 7, wherein the temperature of the aqueous phase component mixed with water in the step (1) is 80 to 85 ℃;
preferably, the time for mixing the water phase component and the water in the step (1) is 5-10 min;
preferably, the temperature for mixing the oil phase components in the step (1) is 78-80 ℃;
preferably, the time for mixing the oil phase components in the step (1) is 5-10 min;
preferably, the temperature for mixing and homogenizing in the step (2) is 80-82 ℃;
preferably, the mixing and homogenizing time in the step (2) is 10-15 min;
preferably, the temperature of the mixing in the step (3) is 40-45 ℃;
preferably, the mixing time in step (3) is 10-20 min.
9. The method according to claim 7 or 8, characterized in that it comprises the steps of:
(1) adding humectant, emulsifier, skin conditioner, emollient and water phase components and water into water phase pot, stirring and mixing at 80-85 deg.C for 5-10min to obtain water phase mixed solution; adding oil phase components of humectant, emulsifier, skin conditioner, and emollient into oil phase pot, stirring and mixing at 78-80 deg.C for 5-10min to obtain oil phase mixed solution;
(2) pumping the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) into an emulsifying pot, and mixing and homogenizing at 80-82 ℃ for 10-15min to obtain a homogeneous liquid;
(3) mixing the homogenized solution obtained in step (2) with the breast-enlarging plant composition of claim 1 or 2 at 40-45 deg.C under stirring for 10-20min to obtain breast-enlarging cream.
10. The method according to any one of claims 7 to 9, characterized by comprising the steps of:
(1) adding humectant, emulsifier, skin conditioner, emollient, thickener and water into water phase pot, stirring and mixing at 80-85 deg.C for 5-10min to obtain water phase mixed solution; adding oil phase components of humectant, emulsifier, skin conditioner, emollient, and thickener into oil phase pot, stirring and mixing at 78-80 deg.C for 5-10min to obtain oil phase mixed solution;
(2) pumping the water phase mixed liquor and the oil phase mixed liquor obtained in the step (1) into an emulsifying pot, and mixing and homogenizing at 80-82 ℃ for 10-15min to obtain a homogeneous liquid;
(3) mixing the homogenized solution obtained in step (2) with the breast enhancement plant composition of claim 1 or 2, antiseptic, pH regulator and essence at 40-45 deg.C under stirring for 10-20min to obtain breast enhancement cream.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911047151.1A CN110585103A (en) | 2019-10-30 | 2019-10-30 | Breast enlarging plant composition, breast enlarging cream and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911047151.1A CN110585103A (en) | 2019-10-30 | 2019-10-30 | Breast enlarging plant composition, breast enlarging cream and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110585103A true CN110585103A (en) | 2019-12-20 |
Family
ID=68851916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911047151.1A Pending CN110585103A (en) | 2019-10-30 | 2019-10-30 | Breast enlarging plant composition, breast enlarging cream and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110585103A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112641697A (en) * | 2020-12-17 | 2021-04-13 | 香港譜康生物技術有限公司 | Non-hormone nutrient cream for increasing chest fat and increasing collagen and preparation method thereof |
| CN113304090A (en) * | 2021-06-11 | 2021-08-27 | 上海奈姿医疗美容门诊部有限公司 | Composition for functionally regulating cell membrane |
| CN114767818A (en) * | 2022-05-18 | 2022-07-22 | 百臻堂国际贸易有限公司 | External composition with breast enlargement and female breast lobular hyperplasia improvement functions |
| CN115154380A (en) * | 2022-06-02 | 2022-10-11 | 允斌(上海)健康科技有限公司 | Breast skin soothing massage cream for breast health care and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120012904A (en) * | 2010-08-03 | 2012-02-13 | (주)아토즈바이오 | Cosmetic compositions for improving breast augmentation or skin elasticity |
| CN105919880A (en) * | 2016-06-13 | 2016-09-07 | 杨海论 | Breast enlargement and beauty cream |
| CN106389914A (en) * | 2016-11-09 | 2017-02-15 | 李宪中 | Hormone-free breast enlarging and beautifying maintenance preparation |
| CN107468614A (en) * | 2017-09-07 | 2017-12-15 | 广东美速健康科技有限公司 | Breast beautifying composition, breast beautifying liquid and preparation method thereof |
| CN107582461A (en) * | 2017-10-18 | 2018-01-16 | 佛山娇芙生物科技有限公司 | A kind of cosmetic composition and emulsion with function of breast augmentation |
| CN108295120A (en) * | 2017-09-19 | 2018-07-20 | 陈淑珍 | A kind of creme making breast enlargement beauty |
-
2019
- 2019-10-30 CN CN201911047151.1A patent/CN110585103A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120012904A (en) * | 2010-08-03 | 2012-02-13 | (주)아토즈바이오 | Cosmetic compositions for improving breast augmentation or skin elasticity |
| CN105919880A (en) * | 2016-06-13 | 2016-09-07 | 杨海论 | Breast enlargement and beauty cream |
| CN106389914A (en) * | 2016-11-09 | 2017-02-15 | 李宪中 | Hormone-free breast enlarging and beautifying maintenance preparation |
| CN107468614A (en) * | 2017-09-07 | 2017-12-15 | 广东美速健康科技有限公司 | Breast beautifying composition, breast beautifying liquid and preparation method thereof |
| CN108295120A (en) * | 2017-09-19 | 2018-07-20 | 陈淑珍 | A kind of creme making breast enlargement beauty |
| CN107582461A (en) * | 2017-10-18 | 2018-01-16 | 佛山娇芙生物科技有限公司 | A kind of cosmetic composition and emulsion with function of breast augmentation |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112641697A (en) * | 2020-12-17 | 2021-04-13 | 香港譜康生物技術有限公司 | Non-hormone nutrient cream for increasing chest fat and increasing collagen and preparation method thereof |
| CN112641697B (en) * | 2020-12-17 | 2024-01-30 | 香港譜康生物技術有限公司 | Nutrient cream for increasing chest fat and increasing collagen by non-hormone and preparation method thereof |
| CN113304090A (en) * | 2021-06-11 | 2021-08-27 | 上海奈姿医疗美容门诊部有限公司 | Composition for functionally regulating cell membrane |
| CN114767818A (en) * | 2022-05-18 | 2022-07-22 | 百臻堂国际贸易有限公司 | External composition with breast enlargement and female breast lobular hyperplasia improvement functions |
| CN115154380A (en) * | 2022-06-02 | 2022-10-11 | 允斌(上海)健康科技有限公司 | Breast skin soothing massage cream for breast health care and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110585103A (en) | Breast enlarging plant composition, breast enlarging cream and preparation method | |
| US7300649B2 (en) | Cosmetic and cosmeceutical compositions for restoration of skin barrier function | |
| CN106880551B (en) | Body lotion for tightening, moistening and smoothing skin and preparation method thereof | |
| JP4563521B2 (en) | Collagen production promoter and topical skin preparation | |
| CN107753332B (en) | A kind of multiple-effect ointment | |
| CN103989601B (en) | A kind of shining tender skin face cream of face moisturizing and preparation method thereof | |
| CN114159347B (en) | Composition with whitening and repairing effects and preparation method and application thereof | |
| CN109010216A (en) | A kind of whitening cosmetics and preparation method thereof | |
| CN113693962A (en) | Fibronectin-containing multiple protein repair composition and preparation method thereof | |
| CN106727122B (en) | Skin care emulsion for fading striae gravidarum and preparation method thereof | |
| CN111374924A (en) | Baby wheat fresh extract raw pulp hip-protecting cream and preparation method thereof | |
| FR2767059A1 (en) | USE OF POLYGONATUM EXTRACTS TO STIMULATE THE SYNTHESIS OF SKIN ELASTIN | |
| CN108785163A (en) | Chest enlarge emulsifiable paste and preparation method thereof and application method | |
| CN108354864B (en) | Preparation method of emulsion with whitening and moisturizing effects | |
| CN110638693A (en) | Compound essential oil for removing striae gravidarum and preparation method and application thereof | |
| CN110680766A (en) | Sterol anti-wrinkle cosmetic and preparation method thereof | |
| CN103006477A (en) | Camellia oil emollient cream | |
| CN110897924B (en) | Repairing composition, application and cosmetic containing same | |
| CN111358710A (en) | Moisture-preserving and soothing donkey-hide gelatin face cream and preparation method thereof | |
| CN107496286B (en) | Water-replenishing and moistening type water emulsion capable of fading fine wrinkles and preparation method thereof | |
| CN110721101A (en) | Self-prepared two-component essence cream and preparation method thereof | |
| CN115487088A (en) | Cosmetic composition containing oleanolic acid and application thereof | |
| CN115590772A (en) | Double-layer essential oil with anti-wrinkle repairing effect and preparation method thereof | |
| CN110613653A (en) | Breast enlarging essential oil and preparation method and application thereof | |
| RU2571273C1 (en) | Biologically active composition for intensive moisturising and lifting effect of skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191220 |